Search clinical trials for: CYT107

Total 70 results

National Institute of Allergy and Infectious Diseases...

Terminated

Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)

Idiopathic CD4+ T-Lymphocytopenia

United States
Cytheris SA

Terminated

Study on Interleukin-7 (CYT107) in HIV Patients (Inspire 2)

HIV

United States, Canada
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis

Switzerland
Revimmune
C.R.O. ReSolution Latin America S.A.

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) (ILIAD-7-BRA)

COVID-19 | Lymphocytopenia

Brazil
Revimmune
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research... and other collaborators

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) (ILIAD-7-US-O)

COVID-19 | Lymphocytopenia

United States
Revimmune
University Hospital, Limoges; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort (ILIAD-7-FR)

COVID-19 | Lymphocytopenia

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Revimmune
Washington University School of Medicine

Terminated

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Mycobacterium Infections, Nontuberculous

United States
Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Revimmune
Amarex Clinical Research

Terminated

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort (ILIAD-7-UK)

COVID-19 | Lymphocytopenia

United Kingdom
Cytheris SA

Completed

Safety Study of IL-7 in HIV-infected Patients (Inspire)

HIV Infections | Lymphopenia

United States, France, Canada, Italy
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
AsclepiX Therapeutics, Inc.

Recruiting

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) (DISCOVER)

Neovascular Age-related Macular Degeneration

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Revimmune
Washington University School of Medicine; Vanderbilt University School of Medicine

Completed

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)

Severe Sepsis With Septic Shock

United States
Cytheris SA

Terminated

Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders (Inspire 3)

HIV

Switzerland, Italy, South Africa
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO)

Diabetic Macular Edema (DME)

United States
Revimmune
Washington University School of Medicine; University Hospital, Limoges; George...

Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-C&D)

Sepsis, Severe

United States, France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
Cancer Targeted Technology
University of California, San Francisco

Completed

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

Prostate Cancer

United States
Cytos Biotechnology AG

Completed

Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Perennial Allergy to House Dust Mite and/or Cat

Estonia, Latvia, Lithuania
Cancer Targeted Technology
University of California, San Francisco

Completed

CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Cytos Biotechnology AG

Withdrawn

CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids

Asthma

United States
CHABiotech CO., Ltd

Completed

Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer

Solid Tumor

Korea, Republic of
Cytos Biotechnology AG

Completed

CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

Allergic Bronchial Asthma

Germany
Conjupro Biotherapeutics, Inc.

Suspended

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

CD20 Positive Non Hodgkin Lymphoma

United States
Cytos Biotechnology AG

Terminated

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Moderate to Severe Allergic Asthma

United States, Czech Republic, Germany, Hungary, Israel, Poland, Russian Federation, Ukraine
Cytos Biotechnology AG

Completed

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Rhinoconjunctivitis | Allergies

Estonia, Germany, Greece, Latvia, Lithuania, Romania
Cytheris SA

Unknown

Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients (CONVERT)

Chronic Hepatitis B

France, Italy
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Cytos Biotechnology AG

Completed

Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers

Smokers

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Malignant Melanoma

Switzerland
Chordate Medical

Completed

PBASE System Idiopathic Rhinitis Clinical Investigation

Idiopathic Rhinitis

Sweden
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Chordate Medical

Completed

Chordate System Prophylactic Migraine Clinical Investigation

Migraine

Sweden
Cytos Biotechnology AG

Completed

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany, Switzerland
Xenova Biomedix

Unknown

Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma

Brain and Central Nervous System Tumors

United States
Cytos Biotechnology AG

Completed

Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb

Essential Hypertension
Cytos Biotechnology AG

Completed

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Allergic Asthma | Perennial Allergic Rhinoconjunctivitis

Switzerland
Cytos Biotechnology AG

Completed

Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy

Hypersensitivity

Switzerland
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Melanoma

Germany
Cytos Biotechnology AG

Completed

Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension

Mild Essential Hypertension | Moderate Essential Hypertension

Switzerland
Zhejiang University

Not yet recruiting

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Metastatic Tumor
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma

Glioblastoma Multiforme

Australia
Cytos Biotechnology AG

Completed

Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension

Hypertension

Switzerland, Germany
Children's Hospital of Fudan University
Hedu Biotechnology (Shanghai) Co., LTD

Recruiting

Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria

Phenylketonuria

China
Novartis Pharmaceuticals

Completed

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection (GuideView)

Prostatic Neoplasms | Prostate Cancer

Spain, Italy, France, Switzerland, United States
Cancer Targeted Technology
National Cancer Institute (NCI); University of California, San Francisco

Completed

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: CYT107

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations